Novartis To Take Back Lamisil Chinese Rights From GSK
This article was originally published in PharmAsia News
Executive Summary
The seven-year itch has struck the successful partnership between Novartis and GlaxoSmithKline. In 2001, GSK's subsidiary in China TSKF secured the rights to develop Lamisil (terbinafine) tablet from Novartis, as well as to produce and sell Lamisil cream. GSK was able to expand the drug's market share in the country rapidly from 2 percent to 12 percent. However, Novartis recently confirmed that it has granted exclusive selling rights for the tablet in China to Profex, a dermatology products company based in Shanghai. Novartis has been strengthening its OTC sector and one priority is to get back itsLamisil cream. GSK is not surrendering the product immediately; meanwhile, it is sparing no effort in promoting its own dermatology drug Bactroban (mupirocin). (Click here for more - Chinese Language)
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.